Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Morning Vas
I liked TO’s post on the Hewitt review and looking on the company’s twitter feed it has received over 300 visits. The company have shown that bleepa can reduce referrals and save costs it just remains to be seen whether trusts will invest in the technology to make their systems more efficient or make do with WhatsApp and other more archaic systems. I looked at the published minutes for QVH for May and it seems the digital pathway was reported as successful at year end and they are looking at the tender process post 15th May. Other trusts have this as an exemplar to use just seems the take up is slow but this is the NHS.
Like you say hopefully an update will bring some positive news both in uk and India.
Not sure if this has been posted before bleepa- carelocker listed on government’s digital marketplace.
https://www.applytosupply.digitalmarketplace.service.gov.uk/g-cloud/services/752336827688660
One of the highlights on the bleepa stand “Deliver rapid cancer diagnostic pathways” . This is what is important to NHS at the moment due to cancer backlog seems like FDBK picking up on this priority.
https://twitter.com/fbkmed/status/1668923904587333633?s=46&t=v-tjWz7Ch513H3G09ffG9g
An overview on current state of digital health in UK
https://www.abhi.org.uk/who-we-are/member-groups/digital-health/
Interesting article on social care
https://www.computerweekly.com/news/365534924/Government-to-pump-more-than-100m-into-digital-social-care
https://www.computerweekly.com/news/365534924/Government-to-pump-more-than-100m-into-digital-social-care
Another contract ripe for FDBK and bleepa. There is no shortage of contracts FDBK should be going for all these opportunities
https://www.contractsfinder.service.gov.uk/notice/0b408954-9099-473b-ae61-f725b4d7286f?origin=SearchResults&p=1
FDBK should be tweeting that they welcome nearly £1bn being allocated towards digital health care and how they see this as an opportunity. The comms is terrible. It shouldn’t be left to investors to dig around for information they can find.
Yes Barnacle my eyes nearly popped out when I saw the total amount allocated. Even if a small fraction of the budget could be allocated towards digital upgrades of CDCs then that would do a lot for FDBK. I hope TO has something to say regarding this new allocation of funds in the half yearly update.
Sorry bidstats not working this was on the government page same allocation of funds for digital services.
https://www.contractsfinder.service.gov.uk/notice/460703bc-9dcb-4f7d-b537-31afe3f08eaa?origin=SearchResults&p=1
Saw this and looks relevant to FDBK, a large chunk of government money available for digital care.
https://bidstats.uk/tenders/2023/W22/799867190
Amazon stock back up now and they report having sold 1k + in past month. There are some bad reviews but with this many sales if it wasn’t working for the majority there would be far more bad reviews. 8 or so bad reviews amongst over 1000 purchases really isn’t telling the true picture.
Https://www.fda.gov/patients/learn-about-drug-and-device-approvals/device-development-process#:~:text=Devices%20undergo%20laboratory%20and%20animal%20testing%20to%20answer%20basic%20questions%20about%20safety.&text=Devices%20are%20tested%20on%20people,they%20are%20safe%20and%20effective.&text=FDA%20review%20teams%20thoroughly%20examine,or%20not%20to%20approve%20it.
This is more information on FDA approval process. By law FDA must publish its decision with all supporting evidence in the Federal register. So there have to be good reasons why FDA reject an application. Agree as FUM are applying for OTC big pharma will see this as disrupting their model of ED treatment of doctor and prescription drug. But I don’t think they will know how successful Eroxon has been before end of June.
This link looks at 4 of the major requirements for class II medical devices. There is nothing here that FUM have not already addressed.
https://www.qualio.com/blog/4-major-class-ii-medical-device-requirements
FUM have done everything they possibly can to warrant FDA approval. They have consulted FDA on leaflet design so that purchasers are aware of other factors that can cause ED. The trial reached primary and secondary endpoints and the safety and technical data has been passed by FDA. The factors that could go against FUM are pressure from big pharma, pressure from doctors eager to keep seeing patients or the FDA deciding it’s not appropriate to have OTC for ED in US. These are the competing issues but the company anticipates approval before end of the month and they are more qualified to give an opinion given they have already dealt with EMA.